Provider Briefing: Apremilast Access in 2026

Apremilast (Otezla/Otezla XR) remains a cornerstone oral therapy for plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. While there is no FDA-reported supply shortage, your patients are likely experiencing significant access barriers that mimic shortage conditions.

This briefing covers the current state of Apremilast availability, prescribing considerations, and practical tools to help your patients access their medication.

Timeline: Apremilast Access Landscape

Understanding the current situation requires context:

• 2014: FDA approves Apremilast (Otezla) for psoriatic arthritis and plaque psoriasis (systemic therapy candidates)
• 2019: Amgen acquires Otezla from Celgene/Bristol-Myers Squibb for $13.4 billion
• 2019: FDA approves Apremilast for oral ulcers in Behçet's disease
• 2021: FDA expands indication to all adult plaque psoriasis (removing severity limitation)
• 2024-2025: FDA approves generic apremilast ANDAs, but patent litigation blocks commercial launch
• 2025: FDA approves Otezla XR (75 mg extended-release, once-daily dosing)
• 2026: No generic available; patent protection expected through 2028-2029

Prescribing Implications

Current Indications

Apremilast is FDA-approved for:

• Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy
• Plaque psoriasis in pediatric patients ≥20 kg
• Active psoriatic arthritis in adults
• Oral ulcers associated with Behçet's disease in adults

Dosing Considerations

Two formulations are now available:

• Otezla: 30 mg twice daily after a 5-day titration (10 mg → 20 mg → 30 mg BID). Titration reduces GI side effects.
• Otezla XR: 75 mg once daily, no titration required. May improve adherence for patients who struggle with BID dosing.

For patients with severe renal impairment (CrCl <30 mL/min), reduce standard Otezla dose to 30 mg once daily.

Key Monitoring Points

• Weight: Monitor regularly; unexplained weight loss of ≥5% should prompt clinical evaluation
• Mood: Screen for depression and suicidal ideation, particularly in patients with a history of mood disorders
• Renal function: Dose adjustment needed for severe impairment
• GI tolerance: Most common reason for discontinuation; the titration schedule is essential

Drug Interactions

The primary interaction concern is with strong CYP450 inducers:

• Rifampin reduces Apremilast AUC by 72% and Cmax by 43%
• Other inducers to avoid: phenobarbital, carbamazepine, phenytoin
• St. John's Wort may also reduce efficacy

No significant interactions with methotrexate, oral contraceptives, or ketoconazole. For a comprehensive list, see our Apremilast drug interactions guide.

Availability Picture

Despite adequate manufacturing supply, patients face multiple access barriers:

Specialty Pharmacy Distribution

Apremilast is distributed exclusively through specialty pharmacy channels. Retail pharmacies generally do not stock it. This means:

• Prescriptions must be directed to approved specialty pharmacies
• Processing time is typically 3-7 business days for new starts
• Patients cannot get same-day fills in urgent situations
• Consider keeping starter pack samples in your office for bridging

Prior Authorization Requirements

Virtually all payers require PA for Apremilast. Common requirements include:

• Documented diagnosis of an approved indication
• Step therapy failure (typically methotrexate for psoriasis/PsA, though requirements vary by plan)
• Prescriber specialty verification (some plans restrict to dermatology or rheumatology)
• Annual reauthorization

Electronic prior authorization (ePA) through your EHR can streamline the process. Amgen provides PA checklists at otezlapro.com.

Patent and Generic Status

Generic apremilast has received FDA tentative approval, but patent litigation has blocked U.S. commercial launch until approximately 2028-2029. This means no generic price competition for at least two more years.

Cost and Access Landscape

• WAC (list price): ~$5,000/month
• Average retail cash price: $5,000-$6,800/month
• Commercial insurance with copay card: As low as $0/month
• Medicare Part D: Specialty tier; copay varies by plan, often $500+/month

Patient Financial Assistance

Amgen offers several support programs through Amgen SupportPlus (1-833-442-6436):

• Co-Pay Program: Eligible commercially insured patients may pay $0
• Bridge to Commercial Coverage: Free medication for up to 12 fills while PA is pending
• Safety Net Foundation: Free medication for uninsured/underinsured patients meeting income criteria

For patients who need additional savings options, refer them to our Apremilast savings guide.

Tools and Resources for Providers

Medfinder for Providers

Medfinder's provider platform helps you and your patients locate pharmacies with Apremilast in stock, reducing the time spent on phone calls and faxes to find availability.

Streamlining Your Workflow

Consider these practice-level strategies to reduce Apremilast access issues:

1. Submit PA at the time of prescribing — don't wait for the specialty pharmacy to identify the need
2. Use ePA through your EHR when available for faster turnaround
3. Document step therapy failures clearly in your notes to support PA submissions and appeals
4. Enroll patients in Amgen SupportPlus at the point of prescribing using the START form
5. Keep Otezla starter pack samples for patients who need to bridge while awaiting insurance approval

When to Consider Alternatives

If a patient cannot access Apremilast despite support interventions, consider:

• Methotrexate: First-line oral systemic, widely available, affordable (~$15-$30/month generic)
• Deucravacitinib (Sotyktu): Oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
• Biologics: TNF inhibitors (adalimumab biosimilars), IL-17 inhibitors (secukinumab), or IL-23 inhibitors as clinically appropriate

For patient-facing information on alternatives, see our guide: Alternatives to Apremilast. For provider guidance on helping patients navigate access challenges, see our provider's guide to finding Apremilast in stock.

Looking Ahead

Several developments may change the Apremilast access picture in the coming years:

• Generic entry (2028-2029): Will significantly reduce costs and expand distribution channels
• Otezla XR adoption: Once-daily dosing may improve adherence and simplify specialty pharmacy logistics
• Expanding oral options: New TYK2 inhibitors and other oral therapies in the pipeline may provide additional options
• Medicare drug pricing reforms: Potential future inclusion in Medicare price negotiation could affect out-of-pocket costs

Final Thoughts

Apremilast remains a well-tolerated, effective oral option for psoriatic disease and Behçet's-related oral ulcers. The primary challenge in 2026 isn't supply — it's navigating the access system efficiently. Proactive PA submission, patient enrollment in support programs, and tools like Medfinder for Providers can significantly reduce the friction your patients experience.

For questions about specific formulary placement or PA requirements for your patients' plans, contact Amgen Medical Information at 1-800-772-6436.